
|Articles|June 1, 2005
Men with cT3 PCa may benefit from surgery
San Antonio--Urologists who might have bypassed the option of surgery to send patients with clinical T3 (cT3) disease directly to a radiation oncologist might want to rethink the way they refer patients, according to a new study.
Advertisement
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Urology Times
1
Published data show DFS benefit with aglatimagene besadenovec in localized prostate cancer
2
Study suggests potential diuretic effect with nadofaragene firadenovec
3
The UroOnc Minute: MDT for Oligometastatic Prostate Cancer, with Chad Tang, MD
4
Clint Bahler, MD, reflects on precision medicine and focal therapy highlights at AUA 2026
5











